Alexander L. Antaris

TL;DR: The screened NIR dyes are identified to possess a bright emission tail in the NIR‐II region along with high quantum yield, high molar‐extinction coefficient, rapid fecal excretion, and functional groups amenable for bioconjugation, facilitating the translation of Nir‐II bioimaging to clinical theranostic applications.

TL;DR: This review focuses on the significant advantage of imaging past 1000 nm with NIR-I fluorophores from both a basic and clinical viewpoint, and discusses optimizing N IR-I dyes around their Nir-II/shortwave infrared (SWIR) emission,NIR-II emission tail characteristics and prospects of NIR/SWIR imaging with clinically available and commercially available dyes.

TL;DR: This study engineered a supramolecular assembly of protein complex with lodged cyanine dyes to produce a brilliant NIR-II fluorophore, providing a Nir-II quantum yield of 21.2% with prolonged circulation time and afforded high-resolution microvessel imaging.

TL;DR: A multiplexed‐near‐infrared‐II (Nir‐II) in vivo imaging system using nonoverlapping NIR‐II probes with markedly suppressed photon scattering and zero‐autofluorescence is reported, which enables visualization of the metastatic tumor and the tumor metastatic proximal LNs resection.

TL;DR: It is shown that AND-gate optical imaging probes that require the processing of two substrates by multiple tumour-specific enzymes produce a fluorescent signal with significantly improved specificity and sensitivity to tumour tissue.